secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-126749
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology appoints Alan Sandler as CMO; CFO Garcia departs with separation agreement
--------------------------------------------------------------------------------

- Alan Sandler, M.D., appointed Chief Medical Officer effective Nov 10, 2024; base salary $575k, signing bonus $50k, 700k stock options.
- Former CFO Peter Garcia resigned Nov 8, 2024; receives $479,646 lump sum, COBRA for 12 months, accelerated equity vesting, and consulting role.
- Board reduced to 4 directors; committees set: Audit (Hemrajani chair), Compensation (Goodman chair), Governance (Garland chair).
- Dr. Sandler brings 30+ years experience from Mirati, Genentech, Zai Lab; will lead evorpacept development into late-stage trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024126749/0000950170-24-126749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024126749/alxo-20241108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer